Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells

Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and high resistance to chemotherapy. Doxorubicin is commonly used, but its efficacy is limited by variable sensitivity and resistance. Bacopaside II, a saponin compound, has shown anti-cancer pot...

Full description

Saved in:
Bibliographic Details
Main Authors: Sima Kianpour Rad, Kenny K. L. Yeo, Runhao Li, Fangmeinuo Wu, Saifei Liu, Saeed Nourmohammadi, William M. Murphy, Yoko Tomita, Timothy J. Price, Wendy V. Ingman, Amanda R. Townsend, Eric Smith
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Biomolecules
Subjects:
triple-negative breast cancer
molecular subtypes
bacopaside II
<i>Bacopa monnieri</i>
doxorubicin
chemotherapy
Online Access:https://www.mdpi.com/2218-273X/15/1/55
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2218-273X/15/1/55

Similar Items